Karin Wingstrand

Board Member

Born in 1957. MSc in Pharmacy, University of Uppsala

Karin comes with extensive knowledge of R&D in the international life science sector. She has held positions such as Global Head of Clinical Development and Global Head of Pharmaceutical and Analytical R&D at AstraZeneca. She is a senior advisor to pharmaceutical and med-tech organizations and has broad experience as a board member from several life science companies as well as an ‘angel-investments’ company.

Board member since 2019.

Other assignments and positions:

Board member of Mevia AB, T-bo­laget AB, Aqilion AB, Xbrane Biopharma AB, Histolab Products AB, Winkon holding AB and Xintela AB.

Shares in Integrum, own and party holders:

B-Shares: 18,518

Stock option 2019/2022: 20 000

Stock option 2020/2023: 20 000

Stock option 2021/2024: 20 000

Independent in relation to the Company and company management as well as independent in relation to the Company larger shareholders.